Welcome to the UPF Digital Repository

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks



Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks

Thumbnail
Document Type: Article
Version: Published version
Date: 2024
This document is associated with a Creative Common license © 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Thumbnail

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking